Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 19/10/2017
SIETES contiene 92082 citas

 
 
 1 a 20 de 1229 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, Maggioni AP, Marso SP, Öhman P, Pagidipati NJ, Poulter N, Ramachandran A, Zinman B, Hernandez AF, for the EXSCEL Study Group. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2017;377:28 de septiembre. [Ref.ID 102096]
2.Tiene citas relacionadas Cita con resumen
Poewe W, Seppi K. Insulin signalling: new target for Parkinson's treatments?. Lancet 2017;390:1628-30. [Ref.ID 102093]
3.Tiene citas relacionadas Cita con resumen
Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, Chowdhury K, Hibbert S, Budnik N, Zampedri L, Li Y, Avilés-Olmos I, Warner TT, Limousin P, Lees AJ, Greig NH, Tebbs S, Foltynie T. Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet 2017;390:1664-16875. [Ref.ID 102092]
4. Cita con resumen
Patel P, Leeder JS, Piquette-Miller M, Dupuis LL. Aprepitant and fosaprepitant drug interactions: a systematic review. Br J Clin Pharmacol 2017;83:2148-62. [Ref.ID 102081]
7. Cita con resumen
Gorricho J, Garjón J, Alonso A, Celaya MC, Saiz LC, Erviti J, López A. Use of oral antidiabetic agents and risk of community-acquired pneumonia: a nested case–control study. Br J Clin Pharmacol 2017;83:2034-44. [Ref.ID 102029]
8. Cita con resumen
Dimmitt S, Stampfer H, Martin JH. When less is more – Efficacy with less toxicity at the ED50. Br J Clin Pharmacol 2017;83:1365-8. [Ref.ID 101984]
9. Cita con resumen
Driessen JHM, de Vries F, van Onzenoort H, Harvey NC, Neef C, van den Bergh JPW, Vestergaard P, Henry RMA. The use of incretins and fractures – A meta-analysis on population-based real life data. Br J Clin Pharmacol 2017;83:923-6. [Ref.ID 101971]
10.
Hampp C, Pippins J. Pioglitazone and bladder cancer: FDA's assessment. Pharmacoepidemiol Drug Saf 2017;26:117-8. [Ref.ID 101950]
11. Cita con resumen
Hodges NL, Spiller HA, Casavant MJ, Chounthirath T, Smith GA. Non-health care facility medication errors resulting in serious medical outcomes. Clinical Toxicology 2017:1-8. [Ref.ID 101917]
12.Enlace a cita original Cita con resumen
Liu J, Li L, Deng K, Xu C, Busse JW, Vandvik PO, Li S, Guyatt GH, Sun X. Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis. BMJ 2017;357:j2499. [Ref.ID 101630]
13. Cita con resumen
Fralick M, Schneeweiss S, Patorno E. Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor. N Engl J Med 2017;376:2300-2. [Ref.ID 101628]
14. Cita con resumen
Poudel DR, Acharya P, Ghimire S, Dhital R, Bharati R. Burden of hospitalizations related to adverse drug events in the USA: a retrospective analysis from large inpatient database. Pharmacoepidemiol Drug Saf 2017;26:635-41. [Ref.ID 101626]
15. Cita con resumen
Greenway T, Ross JS. US drug marketing: how does promotion correspond with health value?. BMJ 2017;357:j1855. [Ref.ID 101571]
16. Cita con resumen
Larkin I, Ang D, Steinhart J, Chao M, Patterson M, Sah S, Wu T, Schoen-baum M, Hutchins D, Brennan T, Loewen-stein G. Association between academic medical center pharmaceutical detailing policies and physician prescribing. JAMA 2017;317:1785-95. [Ref.ID 101559]
17.Enlace a cita original Cita con resumen
Gorricho J, Garjón J, Alonso A, Celaya MC, Saiz LC, Erviti J, López A. Use of oral antidiabetic agents and risk of community-acquired pneumonia: a nested case-control study. Br J Clin Pharmacol 2017:11 de marzo. [Ref.ID 101545]
18. Cita con resumen
Anónimo. Gliptines: pancréatites. Prescrire 2017;37:262. [Ref.ID 101534]
19. Cita con resumen
Lipska KJ, Yao X, Herrin J, McCoy RG, Ross JS, Steinman MA, Inzucchi SE, Gill TM, Krumholz HM, Shah ND. Trends in drug utilization, glycemic control, and rates of severe hypoglycemia, 2006–2013. Diabetes Care 2017;40:468-75. [Ref.ID 101507]
20. Cita con resumen
Flory J. Will cardiovascular outcomes data on newer diabetes drugs bury the older agents?. JAMA Intern Med 2017;177:301-2. [Ref.ID 101462]
Seleccionar todas
 
 1 a 20 de 1229 siguiente >>